---
layout: post
title: "嘉和生物：GB242英夫利西单抗已获国家药监局批准上市"
date: 2022-03-01 12:46:19 +0800
categories: jiemianxinwen
tags: 界面新闻新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/116.06998" data-code="06998|116|5" data-code2="06998|116|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.06998&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 06998_0" data-code="K 06998|116|5" data-code2="K 06998|116|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>嘉和生物3月1日午间在港交所公告，旗下GB242英夫利西单抗已获中国国家药品监督管理局批准，用于治疗类风湿性关节炎、强直性脊柱炎、银屑病、成人溃疡性结肠炎、成人及6岁以上儿童克罗恩病、瘘管性克罗恩病。<br /></p><p class="em_media">（文章来源：界面新闻）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203012292676353>

[返回界面新闻新闻](//finews.withounder.com/category/jiemianxinwen.html)｜[返回首页](//finews.withounder.com/)